Kinase inhibitors in the treatment of immune-mediated disease.

Abstract

Protein kinases are fundamental components of diverse signaling pathways, including immune cells. Their essential functions have made them effective therapeutic targets. Initially, the expectation was that a high degree of selectivity would be critical; however, with time, the use of "multikinase" inhibitors has expanded. Moreover, the spectrum of diseases in which kinase inhibitors are used has also expanded to include not only malignancies but also immune-mediated diseases. At present, thirteen kinase inhibitors have been approved in the United States, all for oncologic indications. However, there are a growing number of molecules, including several Janus kinase inhibitors, that are being tested in clinical trials for autoimmune diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel diseases. It appears likely that this new class of immunomodulatory drugs will have a major impact on the treatment of immune-mediated diseases in the near future.

• Authors: Apostolos Kontzias, Arian Laurence, Massimo Gadina, John J O'Shea
• Journal: F1000 medicine reports (F1000 Med Rep) Vol. 4 Pg. 5 ( 2012) ISSN: 1757-5931 [Electronic] England
• PMID: 22403586 (Publication Type: Journal Article)